Key Points
- Insider purchase: Director David Hyman bought 10,000 shares on December 12 at C$1.12 each (C$11,200), increasing his holdings to 50,000 shares — a 25% rise valued at about C$56,000.
- Company & stock health: Medicenna is a small-cap (market cap C$88.42M), volatile stock (beta 3.31) trading near C$1.06 with a 52‑week range of C$0.78–C$1.98, and it reported negative EPS (C($0.06) last quarter) along with severely negative margins and return on equity.
Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) insider David Hyman acquired 10,000 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average cost of C$1.12 per share, with a total value of C$11,200.00. Following the transaction, the insider owned 50,000 shares in the company, valued at approximately C$56,000. The trade was a 25.00% increase in their ownership of the stock.
Medicenna Therapeutics Stock Performance
Shares of TSE MDNA opened at C$1.06 on Tuesday. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88. The firm's 50-day moving average price is C$1.33 and its two-hundred day moving average price is C$1.09. Medicenna Therapeutics Corp. has a 52-week low of C$0.78 and a 52-week high of C$1.98. The stock has a market capitalization of C$88.42 million, a P/E ratio of -6.24 and a beta of 3.31.
Medicenna Therapeutics (TSE:MDNA - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%. As a group, sell-side analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.
About Medicenna Therapeutics
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
